Skip to main content
Erschienen in: Journal of Diabetes & Metabolic Disorders 2/2018

26.11.2018 | Research Article

The interaction of dyslipidaemia with glycaemia in an adult population study

verfasst von: Sarah Cuschieri, Josanne Vassallo, Neville Calleja, Christopher Barbara, Julian Mamo

Erschienen in: Journal of Diabetes & Metabolic Disorders | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Individuals with dysglycaemic are prone to dyslipidaemia. Understanding the dyslipidaemic status of dysglycaemic individuals is essential for monitoring and early prevention. The aim was to assess the control of lipidaemia by glycaemic status in a representative adult population.

Methods

A retrospective health examination survey was performed on a sample of adults (n = 3947) in Malta in 2014–6. Sociodemographic data, biochemistry blood tests and anthropometric measurements were gathered. Statistical analysis was performed to evaluate the lipidaemic status and its control across the glycaemic spectrum (normoglycemic, impaired fasting glucose individuals, new diabetics and known diabetics).

Results

The prevalence of uncontrolled dyslipidaemia was 7.75% (CI 95%: 6.69–8.63), among whom 6.97% (CI 95%: 6.21–7.81) were naïve dyslipidaemic. A progressive elevation in both LDL-C and total cholesterol but not triglycerides was present among uncontrolled dyslipidaemia individuals across the glycaemic spectrum. Global dyslipidaemia was present in 19.26% (CI 95%: 18.05–20.52) of the total general population and in 46.59% (CI 95%: 40.49–52.69%) of known diabetics. Most individuals irrespective of lipid status were normoglycaemic.

Conclusions

Dyslipidaemia occurs in the presence of insulin resistance. Dyslipidaemia predominated in the normoglycaemic state irrespective of statins use, indicating the need to manage dyslipidaemia prior to dysglycaemia.
Literatur
1.
Zurück zum Zitat Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs. 2013;73:327–39.CrossRefPubMed Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs. 2013;73:327–39.CrossRefPubMed
2.
Zurück zum Zitat Samatha P, Venkateswarlu MSPV. Lipid profile levels in type 2 diabetes mellitus from the tribal population of Adilabad in Andhra Pradesh, India. J Clin diagnostic Res. 2012;6:590–2. Samatha P, Venkateswarlu MSPV. Lipid profile levels in type 2 diabetes mellitus from the tribal population of Adilabad in Andhra Pradesh, India. J Clin diagnostic Res. 2012;6:590–2.
3.
4.
Zurück zum Zitat Inzucchi SE, Amatruda JM. Lipid management in patients with diabetes: translating guidelines into action. Diabetes Care. 2003;26:1309–11.CrossRefPubMed Inzucchi SE, Amatruda JM. Lipid management in patients with diabetes: translating guidelines into action. Diabetes Care. 2003;26:1309–11.CrossRefPubMed
5.
Zurück zum Zitat Solano MP, Goldberg RB. Lipid Management in Type 2 Diabetes. Clin Diabetes. 2006;24:27–32.CrossRef Solano MP, Goldberg RB. Lipid Management in Type 2 Diabetes. Clin Diabetes. 2006;24:27–32.CrossRef
6.
Zurück zum Zitat Ali F, Jamil H, Anwar SS, Wajid N. Characterization of lipid parameters in diabetic and non-diabetic atherosclerotic patients. J Geriatr Cardiol. 2015;12:37–43.PubMedCentralPubMed Ali F, Jamil H, Anwar SS, Wajid N. Characterization of lipid parameters in diabetic and non-diabetic atherosclerotic patients. J Geriatr Cardiol. 2015;12:37–43.PubMedCentralPubMed
7.
Zurück zum Zitat Barrett-Connor E, Grundy SM, Holdbrook MJ. Plasma lipids and diabetes mellitus in an adult community. Am J Epidemiol. 1982;115:657–63.CrossRefPubMed Barrett-Connor E, Grundy SM, Holdbrook MJ. Plasma lipids and diabetes mellitus in an adult community. Am J Epidemiol. 1982;115:657–63.CrossRefPubMed
8.
Zurück zum Zitat Betteridge DJ. Diabetic dyslipidaemia. Eur J Clin Investig. 1999;29(Suppl 2):12–6.CrossRef Betteridge DJ. Diabetic dyslipidaemia. Eur J Clin Investig. 1999;29(Suppl 2):12–6.CrossRef
9.
Zurück zum Zitat Daniel MJ. Lipid management in patients with type 2 diabetes. Am Heal drug benefits. 2011;4:312–22. Daniel MJ. Lipid management in patients with type 2 diabetes. Am Heal drug benefits. 2011;4:312–22.
10.
Zurück zum Zitat Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. Rev Port Cardiol. 2006;25:865–8. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. Rev Port Cardiol. 2006;25:865–8.
11.
Zurück zum Zitat Cholesterol Treatment Trialists’ (CTT), Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–90.CrossRefPubMedCentral Cholesterol Treatment Trialists’ (CTT), Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–90.CrossRefPubMedCentral
12.
Zurück zum Zitat Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther. 2003;99:95–112.CrossRefPubMed Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther. 2003;99:95–112.CrossRefPubMed
14.
Zurück zum Zitat Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering--are they clinically relevant? Eur Heart J. 2003;24:225–48.CrossRefPubMed Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering--are they clinically relevant? Eur Heart J. 2003;24:225–48.CrossRefPubMed
15.
17.
Zurück zum Zitat Cuschieri S, Malta MJ. Mediterranean diabetes hub – A journey through the years. Malta Med J. 26. Cuschieri S, Malta MJ. Mediterranean diabetes hub – A journey through the years. Malta Med J. 26.
20.
Zurück zum Zitat Hockley T, Gemmill M. European Cholesterol Guidelines Report https://policy-centre.com/wp-content/uploads/2017/04/European-Cholesterol-Guidelines07.pdf (accessed 5 November 2017). Hockley T, Gemmill M. European Cholesterol Guidelines Report https://​policy-centre.​com/​wp-content/​uploads/​2017/​04/​European-Cholesterol-Guidelines07.​pdf (accessed 5 November 2017).
21.
Zurück zum Zitat Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23:469–80.CrossRefPubMed Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23:469–80.CrossRefPubMed
22.
Zurück zum Zitat American Diabetes Association. Classification and Diagnosis of Diabetes. Diabetes Care 2016; 39 Suppl 1: S13–S22. American Diabetes Association. Classification and Diagnosis of Diabetes. Diabetes Care 2016; 39 Suppl 1: S13–S22.
23.
Zurück zum Zitat WHO. Global action plan for the prevention and control of noncommunicable diseases 2013-2020. World Heal Organ. 2013:102. WHO. Global action plan for the prevention and control of noncommunicable diseases 2013-2020. World Heal Organ. 2013:102.
25.
26.
Zurück zum Zitat Goldberg IJ. Diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab. 2001;86:965–71.CrossRefPubMed Goldberg IJ. Diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab. 2001;86:965–71.CrossRefPubMed
27.
Zurück zum Zitat Taskinen M-R, Borén J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis. 2015;239:483–95.CrossRefPubMed Taskinen M-R, Borén J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis. 2015;239:483–95.CrossRefPubMed
28.
Zurück zum Zitat Haffner SM, Mykkänen L, Festa A, et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101:975–80.CrossRefPubMed Haffner SM, Mykkänen L, Festa A, et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101:975–80.CrossRefPubMed
29.
Zurück zum Zitat Avramoglu RK, Basciano H, Adeli K. Lipid and lipoprotein dysregulation in insulin resistant states. Clin Chim Acta. 2006;368:1–19.CrossRefPubMed Avramoglu RK, Basciano H, Adeli K. Lipid and lipoprotein dysregulation in insulin resistant states. Clin Chim Acta. 2006;368:1–19.CrossRefPubMed
30.
Zurück zum Zitat Buse K, Tanaka SHS. Healthy people and healthy profits? Elaborating a conceptual framework for governing the commercial determinants of non-communicable diseases and identifying options for reducing risk exposure. Glob Heal. 2017;13. https://doi.org/10.1186/s12992-017-0255-3. Buse K, Tanaka SHS. Healthy people and healthy profits? Elaborating a conceptual framework for governing the commercial determinants of non-communicable diseases and identifying options for reducing risk exposure. Glob Heal. 2017;13. https://​doi.​org/​10.​1186/​s12992-017-0255-3.
31.
Zurück zum Zitat Daboul MW. A study measuring the effect of high serum triglyceride and cholesterol on glucose elevation in human serum. Oman Med J. 2011;26:109–13.CrossRefPubMedCentralPubMed Daboul MW. A study measuring the effect of high serum triglyceride and cholesterol on glucose elevation in human serum. Oman Med J. 2011;26:109–13.CrossRefPubMedCentralPubMed
32.
Zurück zum Zitat Sattar N. Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia. 2013;56:686–95.CrossRefPubMed Sattar N. Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia. 2013;56:686–95.CrossRefPubMed
34.
Zurück zum Zitat Vanelli M, Pedan A, Liu N, Hoar J, Messier D, Kiarsis K. The role of patient inexperience in medication discontinuation: a retrospective analysis of medication nonpersistence in seven chronic illnesses. Clin Ther. 2009;31:2628–52.CrossRefPubMed Vanelli M, Pedan A, Liu N, Hoar J, Messier D, Kiarsis K. The role of patient inexperience in medication discontinuation: a retrospective analysis of medication nonpersistence in seven chronic illnesses. Clin Ther. 2009;31:2628–52.CrossRefPubMed
35.
Zurück zum Zitat Zullig L, Gellad W, Moaddeb J, et al. Improving diabetes medication adherence: successful, scalable interventions. Patient Prefer Adherence. 2015;9:139.CrossRefPubMedCentralPubMed Zullig L, Gellad W, Moaddeb J, et al. Improving diabetes medication adherence: successful, scalable interventions. Patient Prefer Adherence. 2015;9:139.CrossRefPubMedCentralPubMed
36.
Zurück zum Zitat American Diabetes Association AD. 4. Lifestyle Management. Diabetes Care. 2017;40:S33–43.CrossRef American Diabetes Association AD. 4. Lifestyle Management. Diabetes Care. 2017;40:S33–43.CrossRef
37.
Zurück zum Zitat Thunander Sundbom L, Bingefors K. Women and men report different behaviours in, and reasons for medication non-adherence: a nationwide Swedish survey. Pharm Pract (Granada). 2012;10:207–21.CrossRef Thunander Sundbom L, Bingefors K. Women and men report different behaviours in, and reasons for medication non-adherence: a nationwide Swedish survey. Pharm Pract (Granada). 2012;10:207–21.CrossRef
38.
Zurück zum Zitat Chen S-L, Lee W-L, Liang T, Liao IC. Factors associated with gender differences in medication adherence: a longitudinal study. J Adv Nurs. 2014;70:2031–40.CrossRefPubMed Chen S-L, Lee W-L, Liang T, Liao IC. Factors associated with gender differences in medication adherence: a longitudinal study. J Adv Nurs. 2014;70:2031–40.CrossRefPubMed
Metadaten
Titel
The interaction of dyslipidaemia with glycaemia in an adult population study
verfasst von
Sarah Cuschieri
Josanne Vassallo
Neville Calleja
Christopher Barbara
Julian Mamo
Publikationsdatum
26.11.2018
Verlag
Springer International Publishing
Erschienen in
Journal of Diabetes & Metabolic Disorders / Ausgabe 2/2018
Elektronische ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-018-0377-z

Weitere Artikel der Ausgabe 2/2018

Journal of Diabetes & Metabolic Disorders 2/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.